A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenya
Phase of Trial: Phase IV
Latest Information Update: 21 May 2019
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Acronyms PASSOS
- Sponsors Novartis Pharmaceuticals
- 17 May 2019 Status changed from active, no longer recruiting to completed.
- 11 Feb 2019 Planned End Date changed from 28 Jan 2019 to 28 Feb 2019.
- 11 Feb 2019 Planned primary completion date changed from 28 Jan 2019 to 28 Feb 2019.